{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:56:03Z","timestamp":1776826563444,"version":"3.51.2"},"reference-count":53,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2000,12,1]],"date-time":"2000-12-01T00:00:00Z","timestamp":975628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma"],"published-print":{"date-parts":[[2000,12]]},"DOI":"10.3816\/clm.2000.n.015","type":"journal-article","created":{"date-parts":[[2008,9,11]],"date-time":"2008-09-11T01:09:37Z","timestamp":1221095377000},"page":"186-194","source":"Crossref","is-referenced-by-count":20,"title":["Rituximab Therapy of B-Cell Neoplasms"],"prefix":"10.3816","volume":"1","author":[{"given":"Magdalena","family":"Petryk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Grossbard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2000.n.015_bib1","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/1097-0142(195305)6:3<619::AID-CNCR2820060319>3.0.CO;2-Y","article-title":"The in vivo localization of anti-Wagner osteogenic sarcoma antibody","volume":"6","author":"Pressman","year":"1953","journal-title":"Cancer"},{"key":"10.3816\/CLM.2000.n.015_bib2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"10.3816\/CLM.2000.n.015_bib3","first-page":"3147","article-title":"Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen","volume":"40","author":"Nadler","year":"1980","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2000.n.015_bib4","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1200\/JCO.1998.16.11.3691","article-title":"Monoclonal antibody-based therapies for hematologic malignancies","volume":"16","author":"Multani","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib5","first-page":"637a","article-title":"The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction apoptosis in CD20 positive non- Hodgkin's lymphoma cell lines","volume":"88","author":"Maloney","year":"1996","journal-title":"Blood"},{"key":"10.3816\/CLM.2000.n.015_bib6","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1349-7006.1998.tb03280.x","article-title":"Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody","volume":"89","author":"Taji","year":"1998","journal-title":"Jpn J Cancer Res"},{"key":"10.3816\/CLM.2000.n.015_bib7","first-page":"313","article-title":"Rituximab induces in vitro apoptosis in human chronic lymphocytic leukemia cells independent of complement mediated lysis but requires Fcg receptor ligation","volume":"94","author":"Pearson","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLM.2000.n.015_bib8","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"10.3816\/CLM.2000.n.015_bib9","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib10","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.3816\/CLM.2000.n.015_bib11","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti- CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1023\/A:1008332713631","article-title":"Response criteria for NHL: importance of \u2018normal\u2019 lymph node size and correlations with response rates","volume":"11","author":"Grillo-Lopez","year":"2000","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib13","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.1999.17.6.1851","article-title":"Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab","volume":"17","author":"Davis","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib14","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1023\/A:1008389119525","article-title":"Extended Rituximab (anti- CD20 monoclonal antibody) therapy for relapsed or refractory lowgrade or follicular non-Hodgkin's lymphoma","volume":"10","author":"Piro","year":"1999","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib15","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib16","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","article-title":"Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center","volume":"13","author":"Johnson","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib17","first-page":"262b","article-title":"Rituximab re-treatment can produce prolonged failure-free survival for relapsed indolent B-cell lymphoma","volume":"94","author":"Igarashi","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLM.2000.n.015_bib18","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1182\/blood.V95.10.3052","article-title":"Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma","volume":"95","author":"Hainsworth","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2000.n.015_bib19","first-page":"631a","article-title":"Rituximab as a first-line treatment of patients with follicular lymphoma and a low-burden tumor: clinical and molecular evaluation","volume":"94","author":"Solal-Celigny","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLM.2000.n.015_bib20","first-page":"23a","article-title":"Clinical activity of rituximab in patients who have relapsed following ABMT","volume":"19","author":"Grillo-Lopez","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/cbr.1997.12.177","article-title":"Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs","volume":"12","author":"Demidem","year":"1997","journal-title":"Cancer Biother Radiopharm"},{"key":"10.3816\/CLM.2000.n.015_bib22","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1200\/JCO.1999.17.1.268","article-title":"Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy","volume":"17","author":"Czuczman","year":"1999","journal-title":"J Clin Oncol"},{"issue":"suppl 14","key":"10.3816\/CLM.2000.n.015_bib23","first-page":"88","article-title":"CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma","volume":"26","author":"Czuczman","year":"1999","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib24","first-page":"27a","article-title":"Rituximab (IDEC-C2B8) and CVP chemotherapy in follicular or low grade B-cell lymphoma after relapse: results after 6 months of follow-up","volume":"19","author":"Garcia-Conde","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3816\/CLM.2000.n.013","article-title":"Excellent tolerance of rituximab when given after mitoxantrone-cyclophosphamide: an effective and safe combination for indolent NHL","volume":"1","author":"Emmanouilides","year":"2000","journal-title":"Clin Lymphoma"},{"key":"10.3816\/CLM.2000.n.015_bib26","first-page":"17a","article-title":"Pilot study of Rituxan in combination with fludarabine chemotherapy in patients with low-grade or follicular non-Hodgkin's lymphoma","volume":"18","author":"Czuczman","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib27","first-page":"2644","article-title":"Combination immunotherapy of relapsed or refractory low-grade or follicular non- Hodgkin's lymphoma with rituximab and interferon-alpha-2a","volume":"6","author":"Davis","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2000.n.015_bib28","first-page":"91a","article-title":"Phase II study of rituximab after priming with IFN in patients with relapsed low grade\/follicular B-cell lymphoma","volume":"94","author":"Sacchi","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLM.2000.n.015_bib29","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","article-title":"European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma","volume":"18","author":"Foran","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/11.suppl_1.S117","article-title":"Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response","volume":"11","author":"Foran","year":"2000","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1023\/A:1008301432453","article-title":"The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK)","volume":"11","author":"Ghielmini","year":"2000","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib32","first-page":"631a","article-title":"Rituxan\/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma","volume":"94","author":"Howard","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLM.2000.n.015_bib33","first-page":"1927","article-title":"Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2000.n.015_bib34","first-page":"3a","article-title":"Phase II pilot study of the safety and efficacy of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate- or high-grade NHL","volume":"17","author":"Link","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib35","first-page":"26a","article-title":"Dose-Adjusted Epoch Chemotherapy (CT) and Rituximab (EPOCH-R): an Effective Regimen in Poor Prognosis Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)","volume":"19","author":"Gutierrez","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib36","first-page":"44a","article-title":"Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide (CDE) plus the anti-CD20 monoclonal antibody rituximab in HIV-associated non-Hodgkin's lymphoma (NHL)","volume":"19","author":"Tirelli","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib37","first-page":"105a","article-title":"Phase I\/II study of rituxan in chronic lymphocytic leukemia (CLL)","volume":"92","author":"O'Brien","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2000.n.015_bib38","first-page":"704a","article-title":"Phase I\/II study of thrice weekly rituximab in chronic lymphocytic leukemia\/small lymphocytic lymphoma: a feasible and active regimen","volume":"94","author":"Byrd","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLM.2000.n.015_bib39","first-page":"8a","article-title":"Fludarabine and Cyclophosphamide Combined with Rituxan (FCR) Is a Potent Cytoreductive Regimen as Initial Therapy of Chronic Lymphocytic Leukemia","volume":"19","author":"Keating","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib40","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1200\/JCO.1999.17.3.791","article-title":"Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance","volume":"17","author":"Byrd","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib41","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood.V94.7.2217.419k02_2217_2224","article-title":"Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8)","volume":"94","author":"Winkler","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLM.2000.n.015_bib42","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1023\/A:1008350208019","article-title":"Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity","volume":"10","author":"Byrd","year":"1999","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib43","first-page":"6a","article-title":"Rituximab is an active agent in waldenstroms macroglobulinemia (WM)","volume":"19","author":"Treon","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/annonc\/11.suppl_1.S107","article-title":"Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens","volume":"11","author":"Treon","year":"2000","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib45","first-page":"97","article-title":"Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy","volume":"26","author":"Treon","year":"1999","journal-title":"Semin Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib46","first-page":"34","article-title":"Interferon-\u03b3 induces CD20 expression on multiple myeloma patient and healthy donor plasma cells and augments binding of rituximab. Proceeding of the International Conference on Malignant Lymphoma","volume":"10","author":"Treon","year":"1999","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib47","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1182\/blood.V95.4.1502.004k40_1502_1505","article-title":"CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation","volume":"95","author":"Kuehnle","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2000.n.015_bib48","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/annonc\/11.suppl_1.S113","article-title":"Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients","volume":"11","author":"Milpied","year":"2000","journal-title":"Ann Oncol"},{"key":"10.3816\/CLM.2000.n.015_bib49","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1002\/1097-0142(19931101)72:9<2782::AID-CNCR2820720941>3.0.CO;2-H","article-title":"Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine- prednisone chemotherapy","volume":"72","author":"Garrett","year":"1993","journal-title":"Cancer"},{"key":"10.3816\/CLM.2000.n.015_bib50","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1056\/NEJM199404283301703","article-title":"Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation","volume":"330","author":"Papadopoulos","year":"1994","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2000.n.015_bib51","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood.V92.5.1549","article-title":"Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients","volume":"92","author":"Rooney","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2000.n.015_bib52","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJM199105233242102","article-title":"Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation","volume":"324","author":"Fisher","year":"1991","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2000.n.015_bib53","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1182\/blood.V92.9.3137","article-title":"Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome","volume":"92","author":"Benkerrou","year":"1998","journal-title":"Blood"}],"container-title":["Clinical Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526965511702172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526965511702172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T06:08:48Z","timestamp":1588918128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526965511702172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,12]]}},"alternative-id":["S1526965511702172"],"URL":"https:\/\/doi.org\/10.3816\/clm.2000.n.015","relation":{},"ISSN":["1526-9655"],"issn-type":[{"value":"1526-9655","type":"print"}],"subject":[],"published":{"date-parts":[[2000,12]]}}}